Yayın: The impact of TFPI on coronary atherosclerotic burden
| dc.contributor.author | Kahraman, S. | |
| dc.contributor.author | Erdim, R. | |
| dc.contributor.author | Helvacioglu, F. | |
| dc.contributor.author | Dogan, A. | |
| dc.contributor.author | Sozer, V | |
| dc.contributor.author | Gunay, D. | |
| dc.contributor.author | Aytekin, S. | |
| dc.contributor.author | Aytekin, V | |
| dc.date.accessioned | 2026-06-27T14:15:10Z | |
| dc.date.issued | 2018 | |
| dc.description.abstract | OBJECTIVES: We aimed to associate a coronary artery disease (CAD) presence and severity with endothelial dysfunction (ED), carotid intima media thickness (CIMT) and Tissue Factor Pathway Inhibitor (TFPI). BACKGROUND: ED has a central role in atherosclerosis. CIMT and TFPI activity are also related with atherosclerosis and CAD. METHODS: In our prospective observational study, 50 patients had CAD and 30 had normal coronary arteries. Endothelial function was evaluated by endothelium-dependent flow-mediated dilatation (FMD) and nitroglycerinemediated dilatation (NMD) measurements. CIMT and Serum TFPI levels were also measured. RESULTS: TFPI was a statistically significant determinant between the two groups with an increased level in CAD (+) group (84.9 +/- 19.3 vs 70.2 +/- 14.7, p = 0.001). There was a positive correlation between CIMT and Gensini (r = 0.34, p = 0.014). There was a strong negative correlation between Gensini and FMD-NMD, statistically significant (FMD: r =-0.715, p < 0.001; NMD: r = -0.718, p < 0.001). CONCLUSION: We observed that ED, increased CIMT and TFPI levels were associated with CAD. Additionally, increased CIMT measurements and decreased FMD and NMD values had a positive correlation with GSS (Tab. 4, Fig. 6, Ref. 50). Text in PDF www.elis.sk. | en |
| dc.description.uri | https://doi.org/10.4149/bll_2018_071 | |
| dc.identifier.doi | 10.4149/bll_2018_071 | |
| dc.identifier.eissn | 1336-0345 | |
| dc.identifier.endpage | 390 | |
| dc.identifier.issn | 0006-9248 | |
| dc.identifier.issue | 6 | |
| dc.identifier.pubmed | 29947240 | |
| dc.identifier.startpage | 385 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14981/58474 | |
| dc.identifier.volume | 119 | |
| dc.identifier.wos | 000436626500011 | |
| dc.language.iso | eng | |
| dc.publisher | COMENIUS UNIV | |
| dc.relation.ispartof | BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY | |
| dc.rights | openAccess | |
| dc.subject | coronary artery disease | |
| dc.subject | endothelial dysfunction | |
| dc.subject | tissue factor pathway inhibitor | |
| dc.subject | FACTOR PATHWAY INHIBITOR | |
| dc.subject | FLOW-MEDIATED VASODILATION | |
| dc.subject | TISSUE FACTOR | |
| dc.subject | HEART-DISEASE | |
| dc.subject | ARTERY-DISEASE | |
| dc.subject | BRACHIAL-ARTERY | |
| dc.subject | PROGNOSTIC VALUE | |
| dc.subject | SMOOTH-MUSCLE | |
| dc.subject | RISK-FACTORS | |
| dc.subject | General & Internal Medicine | |
| dc.title | The impact of TFPI on coronary atherosclerotic burden | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| local.import.source | WOS |